

Mattias Sandström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5001900/publications.pdf>

Version: 2024-02-01

34
papers

2,434
citations

257450

24
h-index

377865

34
g-index

34
all docs

34
docs citations

34
times ranked

2194
citing authors

#	ARTICLE	IF	CITATIONS
1	¹⁷⁷ Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants. <i>Neuroendocrinology</i> , 2021, 111, 330-343.	2.5	31
2	Phase I Study of ^{99m} Tc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 493-499.	5.0	41
3	Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷ Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms. <i>Cancers</i> , 2021, 13, 962.	3.7	25
4	Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using ⁶⁸ Ga-DOTATOC and ⁶⁸ Ga-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2020, 61, 217-221.	5.0	20
5	¹⁷⁷ Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2020, 110, 662-670.	2.5	34
6	In Vivo Instability of ¹⁷⁷ Lu-DOTATATE During Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1337-1340.	5.0	17
7	Personalized radiation dosimetry for PRRT—how many scans are really required?. <i>EJNMMI Physics</i> , 2020, 7, 26.	2.7	21
8	Kidney dosimetry in 777 patients during ¹⁷⁷ Lu-DOTATATE therapy: aspects on extrapolations and measurement time points. <i>EJNMMI Physics</i> , 2020, 7, 73.	2.7	27
9	Optimal composition and position of histidine-containing tags improves biodistribution of ^{99m} Tc-labeled DARPIn G3. <i>Scientific Reports</i> , 2019, 9, 9405.	3.3	34
10	Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷ Lu-DOTATATE. <i>Cancers</i> , 2019, 11, 909.	3.7	56
11	Prospective observational study of ¹⁷⁷ Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 970-988.	6.4	179
12	Kidney dosimetry during ¹⁷⁷ Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance. <i>Acta Oncologica</i> , 2018, 57, 516-521.	1.8	24
13	Parametric Net Influx Rate Images of ⁶⁸ Ga-DOTATOC and ⁶⁸ Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast. <i>Journal of Nuclear Medicine</i> , 2017, 58, 744-749.	5.0	23
14	Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. <i>EJNMMI Physics</i> , 2017, 4, 28.	2.7	65
15	Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. <i>EJNMMI Physics</i> , 2017, 4, 27.	2.7	71
16	Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors. <i>Theranostics</i> , 2016, 6, 93-103.	10.0	53
17	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [⁶⁸ Ga]ABY-025 Affibody PET/CT. <i>Theranostics</i> , 2016, 6, 262-271.	10.0	204
18	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule ⁶⁸ Ga-ABY-025 in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 867-871.	5.0	88

#	ARTICLE	IF	CITATIONS
19	Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1425-1431.	6.4	47
20	Method dependence, observer variability and kidney volumes in radiation dosimetry of ¹⁷⁷ Lu-DOTATATE therapy in patients with neuroendocrine tumours. <i>EJNMMI Physics</i> , 2015, 2, 24.	2.7	36
21	Comparative evaluation of ¹¹¹ In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors. <i>Oncology Reports</i> , 2015, 34, 1042-1048.	2.6	30
22	Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2015, 56, 177-182.	5.0	179
23	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers. <i>Cancer Research</i> , 2015, 75, 4364-4371.	0.9	55
24	¹⁸⁸ Re-Z ^{HER2:V2} , a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1842-1848.	5.0	23
25	First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the ¹¹¹ In-ABY-025 Affibody Molecule. <i>Journal of Nuclear Medicine</i> , 2014, 55, 730-735.	5.0	211
26	Quantitative and Qualitative Inpatient Comparison of ⁶⁸ Ga-DOTATOC and ⁶⁸ Ga-DOTATATE: Net Uptake Rate for Accurate Quantification. <i>Journal of Nuclear Medicine</i> , 2014, 55, 204-210.	5.0	135
27	Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing ¹⁷⁷ Lu-DOTA-Octreotate Treatment. <i>Journal of Nuclear Medicine</i> , 2013, 54, 33-41.	5.0	216
28	Comparative Biodistribution and Radiation Dosimetry of ⁶⁸ Ga-DOTATOC and ⁶⁸ Ga-DOTATATE in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1755-1759.	5.0	123
29	Minor changes in effective half-life during fractionated ¹⁷⁷ Lu-Octreotate therapy. <i>Acta Oncologica</i> , 2012, 51, 86-96.	1.8	54
30	Lessons on Tumour Response: Imaging during Therapy with ¹⁷⁷ Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma. <i>Theranostics</i> , 2012, 2, 459-471.	10.0	24
31	Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 531-539.	6.4	46
32	Individualized dosimetry in patients undergoing therapy with ¹⁷⁷ Lu-DOTA-D-Phe1-Tyr3-octreotate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 212-225.	6.4	152
33	Targeting of <i>HER2</i> -Expressing Tumors Using ¹¹¹ In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1131-1138.	5.0	81
34	Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT. <i>Physics in Medicine and Biology</i> , 2004, 49, 5419-5432.	3.0	9